Funding News

Viatris to Acquire Pacira BioSciences for $1.65 Billion, Betting on Non-Opioid Pain Management

By Mustafa Shariff, Editor in Chief · October 20,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Viatris to Acquire Pacira BioSciences for $1.65 Billion, Betting on Non-Opioid Pain Management

Summary

  • Viatris to acquire Pacira BioSciences for $1.65 billion — Exparel, Zilretta, and the non-opioid pain bet
  • Viatris has announced a $1.65 billion all-cash acquisition of Pacira BioSciences, maker of Exparel and Zilretta. The deal bolsters Viatris's innovative medicines strategy with two commercially proven non-opioid pain products.

"Exparel has cut opioid consumption by up to 78% in surgery — Viatris is buying the future of post-operative pain care."

On 8 October 2026, Pittsburgh-headquartered Viatris Inc. announced it has entered into a definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash — a total equity value of approximately $1.65 billion. Viatris will fund the deal primarily from excess cash, with the remainder from short-term borrowings. The deal expects to close by end of 2026, pending regulatory clearance and a majority tender of Pacira shares. Both companies' boards have unanimously approved the transaction, and Pacira's board recommends that shareholders tender their shares.
What Pacira Brings: Exparel and Zilretta
Pacira's crown jewel is Exparel — bupivacaine liposome injectable suspension — a long-acting local anesthetic that uses multivesicular liposome technology to release bupivacaine gradually over 72+ hours after surgical infiltration. Exparel is approved for postsurgical local analgesia in adults and children, and for three adult nerve blocks (interscaleal brachial plexus, sciatic nerve, and adductor canal). Clinical data has shown Exparel can reduce opioid consumption by up to 78% in the postoperative period — a critically important figure in the context of the US opioid epidemic. The second key product is Zilretta, an extended-release triamcinolone acetonide injection for osteoarthritis knee pain, which uses a proprietary microsphere delivery system. Together, the two products give Viatris a meaningful footprint in the $12+ billion US pain management market.
Strategic Logic: Building an Innovative Medicines Business
Viatris was formed in 2020 through the merger of Mylan and Pfizer's Upjohn unit, creating a global generics and specialty pharma company. While its legacy is in off-patent generics and biosimilars, Viatris has been publicly signalling its intention to build an "innovative medicines" segment with branded, patent-protected products. Acquiring Pacira accelerates this dramatically. Exparel still has meaningful patent protection; Viatris's IP management and lifecycle strategy expertise — honed through decades of generic entry timing — can help it defend and extend Exparel's market leadership. Additionally, Pacira brings a US commercial infrastructure including a specialty sales force, market access capabilities, and global R&D capacity that Viatris will absorb.
Non-Opioid Pain: The Policy and Competitive Tailwind
The acquisition timing reflects a powerful structural tailwind. The US opioid crisis has prompted prescribing changes, liability pressures on healthcare systems, and policy mandates that incentivize non-opioid alternatives. The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation), enacted in the US, specifically improves Medicare reimbursement for non-opioid postsurgical pain treatments including Exparel, removing a reimbursement disadvantage that had historically limited uptake. Viatris is acquiring Pacira just as the legislative and reimbursement environment is turning structurally more favourable.
Financial Impact
Viatris described the deal as "immediately accretive" to its financial guidance metrics. The company expects minimal impact on its gross leverage ratio given the cash-funded nature of the acquisition. Pacira's FY2025 revenue was approximately $720 million, dominated by Exparel. For Viatris — which reported about $15 billion in annual revenue — Pacira adds a high-margin, innovative-product revenue stream that changes the mix of its business meaningfully.
BHC Perspective: Why Non-Opioid Pain Matters for India
India's surgical pain management protocols still rely heavily on opioids in many hospital settings, both because of cost and because non-opioid alternatives like liposomal bupivacaine are either unavailable or unaffordable at scale. As Indian hospitals expand surgical capacity and patient outcomes monitoring improves, the demand for long-acting local anesthetics will grow. Viatris — already a significant player in the Indian generic market — will now have the incentive to evaluate whether products like Exparel can be positioned for the Indian hospital market, particularly in private surgical centres and medical tourism-oriented hospitals. This deal is worth watching for its India implications.
Frequently Asked Questions
Q: What makes Exparel different from regular bupivacaine injections?
A: Standard bupivacaine injections (like plain bupivacaine HCl) wear off within 4-8 hours. Exparel uses a multivesicular liposome delivery system that traps bupivacaine within multiple lipid chambers, releasing it gradually over 72+ hours. This extended duration covers the critical first three days post-surgery, which is when opioid prescribing is highest and addiction risk is greatest.
Q: When is the Viatris-Pacira deal expected to close?
A: Viatris expects the deal to close by the end of 2026. It requires the expiry of the HSR antitrust waiting period (typically 30 days, sometimes extended) and a majority of Pacira shareholders tendering their shares. Given the unanimous board approval and recommended tender, the regulatory clearance is the primary variable.
Q: How does this deal affect Viatris's biosimilars and generics strategy?
A: The Pacira acquisition does not change Viatris's generics and biosimilars business — it operates alongside it as part of the company's multi-segment model. Viatris has described this as additive: its generics and biosimilars business generates the cash flow that funds acquisitions like Pacira, while Pacira's branded innovative products diversify revenue and improve the company's overall margin profile.
Q: Could Exparel or Zilretta reach India under Viatris's ownership?
A: It is possible but not certain. Viatris has a large India commercial presence through its Mylan-heritage operations. However, regulatory approval for novel formulations in India requires separate CDSCO filings, and pricing dynamics in the Indian private hospital market would need to support a business case for Exparel. Post-acquisition, Viatris will likely evaluate the India opportunity as part of its global commercial strategy for both products, but no timeline has been publicly indicated.